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Abstract: Diacylglycerol kinases (DGKs) play a key role in phosphoinositide signaling by removing
diacylglycerol and generating phosphatidic acid. Besides the well-documented role of DGKα and
DGKζ as negative regulators of lymphocyte responses, a robust body of literature points to those
enzymes, and specifically DGKα, as crucial regulators of leukocyte function. Upon neutrophil
stimulation, DGKα activation is necessary for migration and a productive response. The role of
DGKα in neutrophils is evidenced by its aberrant behavior in juvenile periodontitis patients, which
express an inactive DGKα transcript. Together with in vitro experiments, this suggests that DGKs
may represent potential therapeutic targets for disorders where inflammation, and neutrophils in
particular, plays a major role. In this paper we focus on obstructive respiratory diseases, including
asthma and chronic obstructive pulmonary disease (COPD), but also rare genetic diseases such as
alpha-1-antitrypsin deficiency. Indeed, the biological role of DGKα is understudied outside the T
lymphocyte field. The recent wave of research aiming to develop novel and specific inhibitors as well
as KO mice will allow a better understanding of DGK’s role in neutrophilic inflammation. Better
knowledge and pharmacologic tools may also allow DGK to move from the laboratory bench to
clinical trials.
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1. Introduction
In this review we summarize the rapidly increasing body of knowledge that links diacylglycerol
kinases (DGKs) to chronic respiratory diseases. DGKs are lipid kinases that modulate receptor signaling
but also contribute to membrane trafficking and shaping. As neutrophils play a key role in chronic
respiratory diseases, this article focuses on the numerous, but underappreciated, studies that indicate
DGKs, and specifically the α isoform, as key regulators of the neutrophil life cycle.
2. The Diacylglycerol Kinase Family
DGKs are intracellular lipid kinases that phosphorylate diacylglycerol (DAG) to phosphatidic
acid (PA). In mammals, ten DGK coding genes have been identified and classified into five different
subtypes based on the presence of specific regulatory domains [1]. The presence of multiple genes and
several alternative splicing events increases DGK family diversity, leading to a multiplicity of isoforms
with distinct domain structures and expression patterns [2].
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In the C-terminal portion, all isoforms feature a bipartite catalytic domain that identifies this
family of enzymes. Unfortunately, this catalytic domain has never been structurally determined.
However, it contains an ATP binding site where the mutation of a glycine to an aspartate or alanine
renders the DGK kinase dead [3,4]. In addition to the catalytic domain, all DGK isoforms also contain
at least two cysteine-rich domains, a feature homologous to the C1 domain of protein kinase C (PKC),
which binds to phorbol-ester and DAG [5]. These C1 domains were initially suggested to participate
in substrate recognition, however, they are not absolutely required for catalytic activity [6]. The C1
domain proximal to the catalytic domain has an extended region of fifteen amino acids not present in
the C1 domains of other proteins, nor in the other C1 domains of the DGKs. This extended C1 domain
somehow contributes to DGK activity, because mutations or the deletion of this domain significantly
reduce the kinase activity of the enzyme [3]. Surprisingly, only the C1 domains of β and γ DGKs
bind the DAG phorbol-ester analogues [7,8], suggesting that the C1 domains of the other isoforms
putatively act in protein–protein interactions or in regulatory functions [5].
Conversely, a significant divergence between the isoforms instead exists in the N-terminal
regulatory domains, allowing to divide them into five classes on the basis of structural homology
(Figure 1).
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 2 of 17 
 
However, it contains an ATP binding site where the mutation of a glycine to an aspartate or alanine 
renders the DGK kinase dead [3,4]. In addition to the catalytic domain, all DGK isoforms also contain 
at least two cysteine-rich domains, a feature homologous to the C1 domain of protein kinase C (PKC), 
which binds to phorbol-ester and DAG [5]. These C1 domains were initially suggested to participate 
in substrate recognition, however, they are not absolutely required for catalytic activity [6]. The C1 
domain proximal to the catalytic domain has an extended region of fifteen amino acids not present 
in the C1 domains of other proteins, nor in the other C1 domains of the DGKs. This extended C1 
domain somehow contributes to DGK activity, because mutations or the deletion of this domain 
significantly reduce the kinase activity of the enzyme [3]. Surprisingly, only the C1 domains of β and 
γ DGKs bind the DAG phorbol-ester analogues [7,8], suggesting that the C1 domains of the other 
isoforms putatively act in protein–protein interactions or in regulatory functions [5]. 
Conversely, a significant divergence between the isoforms instead exists in the N-terminal 
regulatory domains, allowing to divide them into five classes on the basis of structural homology 
(Figure 1). 
 
Figure 1. Structure of mammalian diacylglycerol kinases (DGKs). All DGKs share a conserved 
catalytic domain composed of a catalytic (DAGKc) and an accessory (DAGKa) subdomain, preceded 
by two or three C1 domains. Isoform-specific regulatory domains include EF hands, the pleckstrin 
homology domain (PH), Ras association domain (RA), sterile alpha motif (SAM), and ankyrin repeats 
(ANK). Low-complexity regions are shown in pink. Domain annotation by SMART [9]. 
Class I—DGKα, DGKβ, and DGKγ are characterized by a conserved N-terminal recoverin 
homology domain and two calcium-binding EF hand motifs regulating membrane association and 
activity [10]. Recent structural studies have illustrated how calcium binding to the EF hand of DGKα 
removes an intramolecular interaction with the C1 domain, allowing the transition to an “open” 
active conformation [11,12]. 
Class II—DGKδ, DGKη, and DGKκ are characterized by an N-terminal plekstrin homology (PH) 
domain mediating the interaction with phosphatidylinositol 4,5-bisphosphate [13] and, putatively, 
proteins. In addition to the PH domain, DGKδ and DGKη also contain a sterile α motif (SAM) at their 
carboxy terminals capable of zinc-dependent oligomerization but also modulates their membrane 
localization [14]. Conversely, DGKκ lacks a SAM domain, but it does contain a C-terminal motif that 
may bind type I PDZ domains [15]. 
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localization [14]. Conversely, DGKκ lacks a SAM domain, but it does contain a C-terminal motif that
may bind type I PDZ domains [15].
Class III—DGK has an N-terminal hydrophobic α helix, preceding its tandem C1 domains, which
is responsible for endoplasmic reticulum localization [16]. Interestingly, DGK is peculiarly selective
for poly-unsaturated fatty acids in position 2 of DAG and permanently associates to the membrane [17].
The constant activity of this isoform contributes to the enrichment of poly-unsaturated fatty acids
in the phosphoinositide pool. Recessive mutations in DGKε results in hemolytic-uremic syndrome,
probably due to reduced availability of poly-unsaturated fatty acids for prostanoid synthesis [18].
Class IV—DGKζ and DGKι contain a myristoyilated alanine-rich protein kinase C substrate domain
(MARKS), which regulates protein–protein interactions and enzyme activity in a PKC-dependent
manner [19,20]. Class IV DGKs also contain a PDZ-binding domain and ankyrin repeats responsible
for protein–protein interactions [21].
Class V—DGKθ contains an N-terminal proline-rich domain, a third cysteine-rich domain, a PH
domain, and a putative Ras-association domain within it [22].
The various mammalian DGKs show remarkably specific expression patterns, with most cells
expressing multiple DGKs. Often, when several DGKs are expressed in tissues or cells, they are from
different subfamilies, suggesting that each subfamily carries out a distinct biological function [23].
The majority of information on DGK’s biological function in neutrophils comes from studies
with inhibitors or patients. Indeed, despite the availability of KO mice for DGKα [24], DGKβ [25],
DGKδ [26], DGKε [27], DGKη [28], DGKι [29], and DGKζ [30], eventual alterations in neutrophil
functions have not been investigated in animal models.
Actual knowledge is based on two commercially available DGK inhibitors (named R59949 and
R59022), which are widely used in vitro [31,32]. They are reported to be selective for calcium-dependent
type I DGK isozymes, and especially DGKα, with IC50 values of 25 and 18 µM, respectively, for R59022
and R59949 [33,34]. However, their use in vivo is severely limited by their reduced solubility and
strong albumin binding [31,35,36]. Several groups attempted to overcome these limitations. Ritanserin
was identified by us and others as a novel inhibitor of DGKα, with an IC50 around 20 µM based on its
structural similarity to R59022 [37]. For this class of inhibitors, structural studies support a contiguous
ligand-binding site composed of C1, DAGKc, and DAGKa domains in the DGKα active site [38,39].
However, the interpretations of data obtained with ritanserin, R59022, and R59949 are complicated by
the observation that they all are combined pharmacological inhibitors of both DGKα and serotonin
receptors in vitro [37]. Ritanserin was indeed originally characterized as a serotonin receptor antagonist
and underwent clinical trials as a potential medicine for the treatment of schizophrenia and substance
dependence [40–52]. Thus, ritanserin is highly promising for drug repurposing, as it is safe for human
use at concentrations sufficient to inhibit DGKα, but it is poorly specific [53]. Interestingly, still
starting from the two commercial inhibitors, we have recently characterized AMB639752, a novel
DGKα-specific inhibitor deprived of serotonin antagonistic activity [54]. Finally, CU-3 is a promising
compound that selectively inhibits DGKα, with an IC50 value of 0.6 µM by acting as an ATP competitive
inhibitor without displacing DAG or phosphatidylserine [55]. However, the structure and reactivity
of CU-3 makes its use unlikely in vivo. Thus, the pharmacological tools available mainly allow the
study of DGKα functions, while studies on inhibitors that target the other DGK isoforms are still
lacking. Moreover, the results obtained may be influenced by the poor selectivity of commercially
available inhibitors.
3. DGKα in Neutrophil Biology
The DAG-mediated activation of conventional PKC and RASGRP4 are essential steps in neutrophil
signal transduction, which leads to the activation of NADPH oxidase activity, cell movement, and
extracellular trap release [56,57]. Conversely, the PA produced by DGKs (and also phospholipase D)
promotes cell adhesion and degranulation [58,59]. Interestingly, in cell-free systems, the activation
of neutrophil’s NADPH oxidase by DAG requires its conversion to PA by an R59022-sensitive DGK
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activity [60]. PA binds to the NADPH oxidase p47 subunit, together with phosphatidylinositol
3,4-bisphosphate, regulating membrane translocation after PKC-mediated phosphorylation [61].
Despite the relevance of the lipids metabolized by DGKs, their role in neutrophil differentiation
is poorly known. In the HL-60 model cell line, only DGKα, DGKδ, DGKε, DGKγ, and DGKζ were
expressed. Notably, DGKα was virtually absent in undifferentiated cells but was strongly upregulated
throughout differentiation. Conversely, DGKε, DGKγ, and DGKζwere expressed in undifferentiated
HL-60 cells but were strongly downregulated throughout differentiation. The inhibition of DGKαwith
R59022 and R59949 led to an acceleration of differentiation and concomitant cell cycle arrest [62]. This
suggests that DGKs, and DGKα in particular, may play a relevant role during neutrophil differentiation.
Conversely, in the same cell model, DGKγ negatively controlled differentiation toward the macrophage
lineage, suggesting an isoform-specific biological role of DGKs during cell linage commitment [63].
Mature neutrophils express several DGK isoforms that undergo selective regulation during
activation. Indeed, all isoforms, apart from DGKβ and DGKι, are detectable by RT-PCR in
neutrophils [64]. Abundant expressions of DGKα, DGKδ, and DGKγ in human neutrophils have been
reported by Oyaizu [65]. Microarray data (Immunological genome project, www.immgen.org) indicate
that, in mice, DGKα and DGKγ are expressed by bone marrow granulocytes more than in splenic-
or thiourea-induced peritoneal neutrophils. Here, DGKδ, DGKθ, and DGKζ are upregulated, while
DGKε and DGKη are substantially stable (Figure 2 based on data from [66]).
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In differentiated human neutrophils, the DGKα inhibitor R59022, at 10 µM, consistently enhances
superoxide generation upon stimulation with fMet-Leu-Phe (fMLP), IgG, opsonized zymosan, LTB4, or
IL-8 [67,68]. This activation is specific, as the release of lysozyme and N-acetyl-beta-glucosaminidase
production triggered by fMLP is not stimulated by R59022. In vitro, the stimulation of human
neutrophils with fMLP induces a large production of DAG, which is essential for downstream signaling.
This DAG is metabolized largely by DGKα, and the diacylglycerol kinase inhibitor R59022 increases its
concentration, indicating that, among DGKs, the α isoform plays a core role [69,70]. This central role of
Int. J. Mol. Sci. 2019, 20, 5673 5 of 17
DGKα is due to selective activation in the membrane compartment by fMLP itself [71]. The retention
of DAG as a result of DGKα inhibition induces a marked stimulation of superoxide production and
potentiates arachidonic acid release via protein kinase C activation [72,73]. Paradoxically, by stimulating
PKCs, the diacylglycerol kinase inhibitor R59022 also induces chemotaxis in resting neutrophils [74].
Multiple genetic defects affecting all stages of neutrophil development, trafficking, transmigration
into tissues, and, in some instances, function, have been linked to exceptionally aggressive forms of
familial periodontitis, which is a disorder characterized by an exaggerated inflammatory response in
the oral mucosa, leading to the destruction of soft tissues and tooth-supporting bone in susceptible
individuals [75].
Impaired neutrophil chemotaxis, exaggerated adhesion, and oxidative burst are observed in
localized aggressive periodontitis (LAP, also known as localized juvenile periodontitis). Interestingly,
DAG is elevated in unstimulated peripheral blood neutrophils from LAP patients. These cells also
showed an enhanced and prolonged elevation of DAG in response to fMLP or zymosan, due to a
decreased metabolism by DGK [76,77]. Significantly reduced chemotactic response, increased adhesion,
and enhanced respiratory burst activity are also observed in R59022-treated normal neutrophils,
suggesting an impairment in DGKα activity in LAP cells [78,79]. Indeed, the diminished RNA
expression of DGKα in neutrophils from LAP patients causes this decreased DGK activity and the
accumulation of DAG [80]. Further molecular studies identified a DGKα transcript that lacks exon
10 (DGKα∆10). DGKα∆10 features a premature stop codon and encodes a membrane-localized,
truncated protein, which is upregulated in LAP neutrophils. The transfection of HL-60 neutrophil-like
cells with the DGKα∆10 splice variant induced an increase in the fMLP-stimulated production of
superoxide anions, replicating the phenotype of LAP neutrophils [81]. These findings support the
hypothesis that at least a subset of LAP is due to aberrant overexpression of the truncated DGKα∆10
and impairment of DAG metabolism in neutrophils. The molecular links between reduced DGKα
activity and reduced neutrophil-mediated immune defects are not clearly established but are generally
attributed to excessive PKC activity. However, as we will discuss in this review, PA and DAG may
regulate multiple components in the neutrophil signaling pathway, suggesting further research on
this subject.
Anti-neutrophil cytoplasmic antibodies (ANCAs) are autoantibodies (predominantly
immunoglobulin G) directed against constituents of neutrophil’s primary granules and lysosomes of
monocytes. Among the several ANCA antigenic targets identified until now, the two more clinically
relevant and best-characterized are myeloperoxidase and proteinase 3. ANCA antigens are not only
secreted by preactivated neutrophils but are also presented on their surfaces, and by binding to
them and to the FC receptor, ANCAs inappropriately lead to the activation of primed neutrophils
and monocytes [82]. Improved adhesion to endothelial cells, dysregulated neutrophil degranulation,
oxidative burst, and NETosis contribute to pathogenesis, leading to small vessel obstructions and
local tissue damage [83]. ANCA IgG induces multiple signaling pathways in neutrophils that,
despite being distinct from normal neutrophil activation, still converge on DGKα. Indeed, DGKα
is selectively activated by ANCA and produces an abnormal increase in PA, which is responsible
for enhancing neutrophil adhesion, in part, through integrin activation [84], but also by binding to
actin-related protein 3 (Arp3) and promoting actin nucleation [58]. If neutrophils are incubated with
the DGK inhibitor R59022 before treatment with ANCAs, they exhibit a reduced capacity to release the
tissue-damaging content of azurophilic granules such as proteases and myeloperoxidase. This release
is restored by PA treatment, demonstrating that DGKα activity also contributes to granule exocytosis.
The downstream effectors of PA involved are presently unknown, however, both Ca2+ influx and the
modulation of membrane fusion are required to restore exocytosis in DGKα-inhibited neutrophils,
suggesting a perturbation of intracellular vesicular dynamics. This involvement of DGKα-produced
PA in membrane trafficking is expected, as DGKs play a pivotal role in intracellular trafficking. DGKα
is known to be required for the assembly of multivesicular bodies, the polarized secretion of exosomes
by T cells [85], and also integrin and MHC complex recycling in epithelial cells. DGKα-produced PA
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mediates the membrane recruitment of several proteins, such as the Rab11 effector RCP and the adaptor
MICAL-1 [86,87]. In addition, other DGK isoforms have been implicated in virtually all aspects of
intracellular membrane trafficking. This is exemplified by DGKζ interactions with sortin-nexin during
endosomal recycling in T cells [88], DGKδ scaffolding activity in the endoplasmic reticulum to the
Golgi traffic [89], and DGKθ in synaptic recycling [90]. The finding that stopping PA production by
inhibiting DGKα impairs both integrin recycling and secretion suggests that DGKα may represent
a viable drug target to reduce tissue injury associated with ANCA-associated vasculitis and other
autoimmune disorders where neutrophils play a major role [91].
4. DGKs in Respiratory Diseases
While several studies have addressed the biological role of DGKs, their impact on respiratory
disease is not completely enlightened and is still under investigation. Asthma and chronic obstructive
pulmonary disease (COPD) are characterized by airflow obstruction and represent the most common
non-communicable respiratory diseases with an increasing worldwide prevalence and impact on
global health.
In relation to asthma, a heterogeneous pattern of inflammatory mechanisms has been identified in
the underlying clinical features. The main phenotypes comprise eosinophilic inflammation and Th1
and Th17 neutrophilic inflammation [92].
Eosinophilic inflammation, and consequent type 2 airway inflammation, occurs in a large number
of patients, and typically about half of asthmatic patients [93]. The main step is represented by allergic
sensitization, where an allergen stimulates dendritic cells that, in the presence of a coactivator, are
conducive to the polarization of T helper lymphocytes in T helper 2. Mediators released in type 2
inflammation include interleukin-4, interleukin-5, and interleukin-13 [92], which stimulate and sustain
eosinophilic activation. In particular, interleukin-5 is essential for the survival of eosinophils, as they
are the only granulocyte that expresses the interleukin-5 receptor [94].
Alongside type 2 inflammation, asthma displays other pathophysiologic patterns underlying
its clinical manifestation. Actually, non-eosinophilic asthma has been described both in the young
and adults [95]. Green et al. reported the presence of an asthmatic sub-group showing neutrophilic
inflammation during the analysis of induced sputum [96]. Here, the trigger allergens and molecular
mechanisms are only partially understood. Neutrophilic inflammation is mainly sustained by T helper
1 lymphocyte cytokines, but also T helper 17 cells and type 3 innate lymphoid cells are recognized as
playing roles in non-eosinophilic inflammatory processes. Macrophages are intermediate actors of this
pathway, mainly releasing neutrophil chemotactic molecules such as CXC motif chemokine ligand 8
(CXCL8) [97]. The protein encoded by this gene is a member of the CXC chemokine family and is a
major mediator of the inflammatory response the binding CXC motif chemokine receptor-1 and -2
(CXCR1 and CXCR2).
In relation to eosinophilic inflammation, Wang et al. [98] conducted an interesting study in a
murine model of allergic asthma. Plasmids containing the DGKα-encoding gene were inoculated in
mice, and asthma was later induced through alum-adsorbed ovalbumin (OVA). Mice “immunized”
with the DGKα gene showed significantly lower allergic airway inflammation and reduced eosinophilic
infiltration in the lungs when compared to mice that did not receive plasmids with the DGKα-encoding
gene. These results suggested a potential critical role of DGKα in allergic and eosinophilic asthma,
where elevated levels of DGKαwere detected in anergic and non-stimulated T-cells, while reduced
levels of DGKαwere found in activated T-cells.
DGKα’s role in non-eosinophilic asthma is less clear. The main actors involved in non-eosinophilic
asthma are type 1 inflammation cells, including Th1, cytotoxic T-lymphocytes (CTL), and neutrophils.
Previous reports have found a reduced transcription of DGKα by IL-2 in CTL [99,100]. CTLs derived
from DGKα-deficient mice showed increased IL-2-dependent proliferation and activation as well as an
enhanced cytotoxic effect [99]. However, DGKα and ζ double deficiency actually has caused the severe
impairment of CD8 T cell-mediated responses, especially in response to bacterial pathogens [101].
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Moreover, Ruffo et al. [35] showed that DGKα inhibition restores correct CTL activity in the
context of genetic predisposition to EBV-driven lymphohistiocytosis. They found that the persistent
activation of DGKα, with subsequent diminishing DAG signaling, lead to the impairment of CTL
functions in patients with X-linked lymphoproliferative disease 1 (XLP-1). Patient CTLs lacked
restimulation-induced cell death (RICD), a crucial self-regulatory apoptosis program triggered by
repeated T cell receptor (TCR) stimulation in order to maintain peripheral immune homeostasis
and avoid the pathological accumulation of activated T cells [102]. In murine models of pathology,
the inhibition of DGKα was demonstrated to provide a reduction of lymphocytic infiltrates in the liver
and bone marrow and of INFγ, suggesting the potential restoration of RICD by CTLs [35].
The complex functions of DGKα have also been reported by Shin et al., who found the inhibitory
roles of DGKα and DGKζ in the primary anti-viral immune response, while they appear to promote
expansion of viral specific memory cytotoxic T cells during secondary infection [103]. The mechanisms
underlying such differential roles of DGK activity in primary and memory anti-viral immunity are
unclear, but they may be related to the dual role of DGKs as negative regulators of TCR signaling and
also mediators of cytokine responses [104].
Sanjuan et al. investigated the role of DGKα in relation to CD69 expression, one of the early
markers of T cell activation in relation to TCR stimulation [105,106]. They demonstrated that DGKα
activation is dependent on its translocation from the cytosol to the membrane and leads to reduction in
DAG signaling and in CD69 expression. The impact of DGKα in T cell activation needs to be better
investigated, but evidence suggests it is not a secondary role in the signaling pathway.
DGK is a physiological modulator of DAG metabolism, limiting PKC activation [107] but also the
activity of other C1-containing proteins, such as chiaerins (a family of Rac GAPs) and RASGRPs (a
group of Ras GEFs) [108]. However, the phosphorylation of DAG by DGK produces PA, which adds to
that produced by the action of phospholipase D (PLD) on glycerophospholipid (Figure 3). PA has long
been considered an intermediate step in the resynthesis of phosphatidylinositol, with no specific role in
the transduction of receptor-derived signals. On the contrary, PA represents a keystone of intracellular
signaling, binding several signaling enzymes such as phosphodiesterases, components of the MAPK
cascade, lipid kinases, and p47phox [109]. In addition, PA generation at the membrane induces a
negative membrane curvature, which precedes changes leading to either membrane fusion or fission.
The regulation of PA generation is, thus, closely linked to the control of exocytosis, endocytosis, and
membrane trafficking [110].
One of the most powerful stimuli of chemotaxis for neutrophils is represented by CXCL8, produced
mainly by macrophages. Neutrophil migration into the respiratory airway represents a crucial step in
COPD progression. Neutrophils secrete serine proteases that act by destroying the alveolar matrix and
have a consequent impact on airway architecture. CXCL8 binds the neutrophil chemokine receptors
CXCR1 and CXCR2. The signaling cascade includes enhancing intracellular Ca2+ levels, with a
subsequent release of granule proteins and chemotaxis [111]. Moreover, the stimulation of CXCR1
leads to the increased release of superoxide anions and to the activation of phospholipase D (PLD) and,
thus, PA production [112].
Acute exacerbation in COPD patients is one of the key parameters that assesses the severity and
the disability of the disease. During acute exacerbation, an increased percentage of neutrophils in the
sputum has been observed. The main explanations involve a higher production of chemotactic factors,
including leukotriene B4 (LTB4) and CXCL8 [113]. More specifically, Sapey et al. investigated the
neutrophil chemotactic response in COPD patients compared to healthy smoking and non-smoking
patients and patients with α1-antitrypsin deficiency (1AAD). They found no differences in receptor
expression on the neutrophil surface across different populations, but the speed of migration was
increased in COPD patient neutrophils with a reduction in migratory accuracy, suggesting impaired
intracellular signaling responses [114].
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PA has been reported to play a central role in cell adhesion and the migration of leukocytes,
especially neutrophils [115,116]. Speranza et al. demonstrated the central role of PA produced by PLD
in regulating leukocyte adhesion by the binding of PA to Arp3, which leads to actin polymerization.
Adhesion is the obligate first step for rolling leukocytes in blood to anchor to the capillary beds around
inflamed or injured tissue, such as that observed in COPD. Moreover, the generation of PA in response
to DGK functions participates in receptor endocytosis [117] and regulates transcription [118,119].
Rainero et al. have enlightened the role of DGKα in integrin trafficking modulation. In particular, they
reported that the inhibition of DGKα consistently reduced the recruitment of RCP, while the inhibition
of PLD had no effect on its recruitment, suggesting that DGKα is more important than PLD as a source
of PA to enable RCP functions [86].
In this direction, the study of Xu et al. investigated the α and β isoforms of PKC in neutrophils,
which are the main isoforms involved in maintaining polarization and chemotaxis. In resting
neutrophils, they are localized in the cytosol, and, after chemoattractant stimulation, they translocate
to the membrane through PLC-dependent signaling, suggesting DAG acts as a major determinant
in their regulation [120]. PKC plays a crucial role in the intracellular signaling network to enhance
neutrophil actions, in particular, neutrophil extracellular trap (NET) release, a neutrophil-specific form
of cell death [56] (Figure 4). The activation of classical PKC by the DAG analog PMA is, indeed, a
classical way to induce NET formation through a signaling pathway that comprises calcium fluxes,
reactive oxygen species generation by NADPH oxidase, and neutrophil elastase activity [121,122].
Interestingly, neutrophils from chronic granulomatous disease patients with genetic defects in the
NADPH oxidase complex do not release NET in response to PMA [121]. Surprisingly, no one has still
directly investigated if DGK activity regulates NET release in vitro or in pathological models.
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Few data are available in relation to idiopathic pulmonary fibrosis (IPF). IPF is a chronic,
progressive, and fatal disease involving lung interstices [123]. The principal pathophysiological
features are represented by excessive extracellular matrix depositions that lead to abnormal lung
architecture. Impaired damage repair has severe consequences up until respiratory failure [124].
Several elements have been indicated as risk factors to develop IDF. Cigarette smoke and bacterial and
viral infections are the main risk factors, followed by radio- and chemo-therapy [125].
Previous studies have suggested the role of PA produced by PLD in the development of kidney
fibrosis [126], in particular, its genetic deletion was linked to the attenuated development of kidney
fibrosis. Based on this concept, Suryadevara et al. [125] studied PLD KO mice in a murine model
of bleomycin-induced lung epithelial injury. Mice without PLD were protected against pulmonary
fibrosis, suggesting a significant role of PL , and, thus, P in the development of pulmonary fibrosis.
Rec ntly, targeting the diacylglycerol et lis ζ knockdown or treatment with the
DGKα-specific inhibitor R59 49 has pro fi ial for treating asthma by reducing both
inflam ation and airway hyper esponsive going studies are evaluating the impact of
DGKα inhibitors in the context of α1-antitrypsin mutations that result in 1AAD. The Glu342 ys (Z
form) p oduces inclusion bodies that are retained in h patocytes rather th n secreted in the circulation.
Those polymers are cytotoxic to hepat cytes and cause liver damage, while decreased levels in the
circulation expose the lung extracellular matrix to degradation by neutrophil elastase [128]. Protein
replacement slows the progression of emphysema but does not resolve the disease [129]. As previously
reported, DGKα is markedly upregulated throughout neutrophil differentiation and is required for
maturation [62]. The activation of DGKα by anti-neutrophil cytoplasmic antibodies inappropriately
stimulates neutrophil adhesion, degranulation, and induces an oxidative burst, which contributes to
the progression of inflammatory disease [84,91].
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5. Discussion
The adjustment of DGK activity offers an innovative perspective in the therapeutic manipulation
of T cell functions for the treatment of autoimmune pathologies. Having specific information on
the mechanisms that sustain DGK isoform-specific regulation in T lymphocytes is crucial for the
development of novel tools for pharmacological intervention [100]. While the biological role of DGKs,
and DGKα and Dgkζ in particular, is well documented in T cells and in adaptive immunity, few studies
have investigated their role in innate immunity. Indeed, neutrophils express multiple DGK isoforms,
but only DGKα has been studied in detail, with several in vivo and ex vivo experiments indicating
it as a key regulator of neutrophil function. Thus, there is a gap in knowledge on the contribution
of the other DGK isoforms to neutrophil biology, as well as on the molecular mechanisms by which
the regulation of DAG and PA pools by DGKs influence leukocyte behaviors. This gap mainly is due
to an underappreciation of the role of those enzymes outside adaptive immunity, but also due to a
lack of suitable tools. Recent advancements in the development of DGKα inhibitors [54,55] and the
availability of murine models deficient of specific DGK isoforms will allow the investigation of the
suitability of those enzymes as targets for neutrophil-mediated diseases, such as chronic diseases of
the respiratory system, and also rare genetic diseases, such as alpha-1-antitrypsin deficiency.
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